(Q57714808)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16691618%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

title

Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16691618%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

0 references

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16691618%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Kenneth J. Pienta

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16691618%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

David C. Smith

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16691618%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

5

Judith Fardig

1 reference

21 January 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16691618%20AND%20SRC:MED&resulttype=core&format=json

Beth Hellerstedt

3

object named as

Beth Hellerstedt

1 reference

21 January 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16691618%20AND%20SRC:MED&resulttype=core&format=json

Niklas J Mackler

1

object named as

Niklas J Mackler

1 reference

21 January 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16691618%20AND%20SRC:MED&resulttype=core&format=json

author name string

Karin Olson

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16691618%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Rodney L Dunn

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16691618%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

language of work or name

English

0 references

publication date

1 June 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16691618%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16691618%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

volume

106

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16691618%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16691618%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

page(s)

2617-2623

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16691618%20AND%20SRC:MED&resulttype=core&format=json

Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer

21 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21927

21 January 2018

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21927

7 January 2021

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21927

7 January 2021

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21927

7 January 2021

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21927

7 January 2021

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21927

7 January 2021

Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21927

7 January 2021

Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubules

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21927

7 January 2021

Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21927

7 January 2021

A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21927

7 January 2021

Some practical improvements in the continual reassessment method for phase I studies.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21927

7 January 2021

Continual reassessment method: a likelihood approach.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21927

7 January 2021

Sequential designs for phase I clinical trials with late-onset toxicities

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21927

7 January 2021

Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21927

7 January 2021

Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21927

7 January 2021

A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21927

7 January 2021

Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21927

7 January 2021

Identifiers

DOI

10.1002/CNCR.21927

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16691618%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference